16 September 2026 editorial review · Item
Dasiglucagon stable-glucagon infusion for bihormonal AID: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: Dasiglucagon stable-glucagon infusion for bihormonal AID
Scope and findings:
- Registry protocol/status/outcome scope checked; NCT05454709: WITHDRAWN, primary completion {'date': '2023-12-29', 'type': 'ESTIMATED'}, {'count': 0, 'type': 'ACTUAL'}. No new results inferred from completion dates; product approval/access and older clinical scores are separate checks.
- Read Q2 2026 SEC filing: first integrated feasibility trial Q4 2025 and additional trial Q1 2026; further excipient and dosing-algorithm improvements identified. Supports early research, not pivotal readiness. Historical dasiglucagon and successor Xeris formulation distinguished; no new trial date established.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.